CAR-T for Chronic Lymphocytic Leukemia Receives FDA Approval.

Published Date: 18 Mar 2024

For CLL/SLL patients who are refractory or have relapsed, lixocabtagene maraleucel (Breyanzi) has a new indication.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study confirms link between breast density, higher breast cancer risk

2.

The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.

3.

By acquiring T3 Pharma, a leader in bacterial cancer treatment, Boehringer Ingelheim broadens its offering in immunooncology.

4.

Is global cancer care losing its human touch?

5.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot